Showing posts with label DRNA. Show all posts
Showing posts with label DRNA. Show all posts
Friday, May 3, 2019
Beyond Meat's IPO leads to a rare 2000-style stock surge
Beyond Meat Inc.’s first day of trading after its initial public offering brought the kind of stock surge that has been relatively rare since 2000, the year that an Internet-driven bull market ended. The producer of vegan beef and sausage substitutes soared 163 percent in its debut. Beyond Meat is only the eighth U.S. company in the past 18 years to climb at least 125 percent after completing an initial public offering of $100 million or more, according to data compiled by Bloomberg. The rest are shown in the chart. There were 29 in 2000 alone.
Thursday, May 12, 2016
Sunday, March 30, 2014
Monday, February 3, 2014
Dicerna Pharmaceuticals Inc (DRNA) began trading on the NASDAQ on 30 January 2014
- Priced 6 million shares of common stock at $15.00 per share.
- Jefferies LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. Robert W. Baird & Co. Incorporated is acting as co-lead manager for the offering.
Description
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company intends to discover, develop and commercialize therapeutics either on its own or in collaboration with pharmaceutical partners. The Company has partnered two of its oncology development programs with the global pharmaceutical company Kyowa Hakko Kirin Co., Ltd. The Company is developing DCR-PH1 for the treatment of the rare and serious inherited disorder PH1 by targeting the liver metabolic enzyme glycolate oxidase.
Address
Building 1 Suite 120, 480 Arsenal Street
WATERTOWN, MA 02472
United States
WATERTOWN, MA 02472
United States
Website :
http://www.dicerna.comKey stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | - | -144.28% |
| Operating margin | - | -131.86% |
| EBITD margin | - | -124.01% |
| Return on average assets | -56.86% | -58.12% |
| Return on average equity | - | - |
| Employees | 24 |
Subscribe to:
Posts (Atom)